The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Leukemia. Bd. 23. H. 1. 2009 S. 153-61
Erscheinungsjahr: 2009
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Buske, C (Autor)
Hoster, E (Autor)
Dreyling, M (Autor)
Eimermacher, H (Autor)
Wandt, H (Autor)
Metzner, B (Autor)
Fuchs, R (Autor)
Bittenbring, J (Autor)
Woermann, B (Autor)
Hohloch, K (Autor)
Hess, G (Autor)
Ludwig, WD (Autor)
Schimke, J (Autor)
Schmitz, S (Autor)
Kneba, M (Autor)
Reiser, M (Autor)
Graeven, U (Autor)
Klapper, W (Autor)
Unterhalt, M (Autor)
Hiddemann, W (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
